StockData
Provectus Biopharmaceuticals, Inc. logo

Provectus Biopharmaceuticals, Inc. (PVCT) stock

PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$0.05+0.00 (+0.39%)

Close on Oct 19, 2026Market cap $20.55MP/E –Yield –

Provectus Biopharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Provectus Biopharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$4.58M. For fiscal 2025 it was -$5.29M. The highest annual figure on record is -$2.90M in fiscal 2023.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$5.29M–
FY2024Dec 31, 2024-$4.53M–
FY2023Dec 31, 2023-$2.90M–
FY2022Dec 31, 2022-$3.43M–
FY2021Dec 31, 2021-$4.67M–
FY2020Dec 31, 2020-$4.96M–
FY2019Dec 31, 2019-$6.30M–
FY2018Dec 31, 2018-$8.05M–
FY2017Dec 31, 2017-$13.32M–
FY2016Dec 31, 2016-$24.51M–
FY2015Dec 31, 2015-$24.65M–
FY2014Dec 31, 2014-$12.63M–
FY2013Dec 31, 2013-$13.03M–
FY2012Dec 31, 2012-$14.34M–
FY2011Dec 31, 2011-$21.44M–
FY2010Dec 31, 2010-$20.69M–
FY2009Dec 31, 2009-$12.33M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$938.68K–
Q1 FY2026Mar 31, 2026-$1.25M–
Q4 FY2025Dec 31, 2025-$1.12M–
Q3 FY2025Sep 30, 2025-$1.28M–
Q2 FY2025Jun 30, 2025-$1.80M–
Q1 FY2025Mar 31, 2025-$1.10M–
Q4 FY2024Dec 31, 2024-$2.33M–
Q3 FY2024Sep 30, 2024-$955.73K–
Q2 FY2024Jun 30, 2024-$794.85K–
Q1 FY2024Mar 31, 2024-$447.27K–
Q4 FY2023Dec 31, 2023-$604.69K–
Q3 FY2023Sep 30, 2023-$714.15K–
Q2 FY2023Jun 30, 2023-$800.20K–
Q1 FY2023Mar 31, 2023-$782.21K–
Q4 FY2022Dec 31, 2022-$683.72K–
Q3 FY2022Sep 30, 2022-$666.19K–
Q2 FY2022Jun 30, 2022-$1.08M–
Q1 FY2022Mar 31, 2022-$1.00M–
Q4 FY2021Dec 31, 2021-$1.22M–
Q3 FY2021Sep 30, 2021-$1.05M–
Q2 FY2021Jun 30, 2021-$1.22M–
Q1 FY2021Mar 31, 2021-$1.18M–
Q4 FY2020Dec 31, 2020-$1.20M–
Q3 FY2020Sep 30, 2020-$1.10M–
Q2 FY2020Jun 30, 2020-$1.21M–
Q1 FY2020Mar 31, 2020-$1.45M–
Q4 FY2019Dec 31, 2019-$1.22M–
Q3 FY2019Sep 30, 2019-$1.44M–
Q2 FY2019Jun 30, 2019-$1.84M–
Q1 FY2019Mar 31, 2019-$1.80M–
Q4 FY2018Dec 31, 2018-$1.90M–
Q3 FY2018Sep 30, 2018-$1.36M–
Q2 FY2018Jun 30, 2018-$2.09M–
Q1 FY2018Mar 31, 2018-$2.70M–
Q4 FY2017Dec 31, 2017-$2.73M–
Q3 FY2017Sep 30, 2017-$2.99M–
Q2 FY2017Jun 30, 2017-$3.30M–
Q1 FY2017Mar 31, 2017-$4.40M–
Q4 FY2016Dec 31, 2016-$5.18M–
Q3 FY2016Sep 30, 2016-$5.78M–

More Provectus Biopharmaceuticals figures

See a number that looks wrong?